|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim JH, Chung JB, Park IS, Kim BS, Yoo NC,
Choi JH, Roh JK, Kim HS, Kwon OH, Lee KS, et al: Combined use of
tamoxifen, cyclosporin A, and verapamil for modulating multidrug
resistance in human hepatocellular carcinoma cell lines. Yonsei Med
J. 34:35–44. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thomas H and Coley HM: Overcoming
multidrug resistance in cancer: An update on the clinical strategy
of inhibiting p-glycoprotein. Cancer Contr. 10:159–165. 2003.
View Article : Google Scholar
|
|
6
|
Ferry DR, Traunecker H and Kerr DJ:
Clinical trials of P-glycoprotein reversal in solid tumours. Eur J
Cancer. 32A:1070–1081. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin SS, Lai KC, Hsu SC, Yang JS, Kuo CL,
Lin JP, Ma YS, Wu CC and Chung JG: Curcumin inhibits the migration
and invasion of human A549 lung cancer cells through the inhibition
of matrix metalloproteinase-2 and −9 and Vascular Endothelial
Growth Factor (VEGF). Cancer Lett. 285:127–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Limtrakul P: Curcumin as chemosensitizer.
Adv Exp Med Biol. 595:269–300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharma RA, Gescher AJ and Steward WP:
Curcumin: The story so far. Eur J Cancer. 41:1955–1968. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anand P, Thomas SG, Kunnumakkara AB,
Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K,
Priyadarsini IK, Rajasekharan KN, et al: Biological activities of
curcumin and its analogues (Congeners) made by man and Mother
Nature. Biochem Pharmacol. 76:1590–1611. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guzzarlamudi S, Singh PK, Pawar VK, Singh
Y, Sharma K, Paliwal SK, Chourasia MK, Ramana MV and Chaurasia M:
Synergistic Chemotherapeutic Activity of Curcumin Bearing
Methoxypolyethylene Glycol-g-Linoleic Acid Based Micelles on Breast
Cancer Cells. J Nanosci Nanotechnol. 16:4180–4190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Colacino JA, McDermott SP, Sartor MA,
Wicha MS and Rozek LS: Transcriptomic profiling of curcumin-treated
human breast stem cells identifies a role for stearoyl-coa
desaturase in breast cancer prevention. Breast Cancer Res Treat.
158:29–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muddineti OS, Kumari P, Ajjarapu S,
Lakhani PM, Bahl R, Ghosh B and Biswas S: Xanthan gum stabilized
PEGylated gold nanoparticles for improved delivery of curcumin in
cancer. Nanotechnology. 27:3251012016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fernald K and Kurokawa M: Evading
apoptosis in cancer. Trends Cell Biol. 23:620–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chapman RS, Whetton AD, Chresta CM and
Dive C: Characterization of drug resistance mediated via the
suppression of apoptosis by Abelson protein tyrosine kinase. Mol
Pharmacol. 48:334–343. 1995.PubMed/NCBI
|
|
18
|
Chapman RS, Whetton AD and Dive C: The
suppression of drug-induced apoptosis by activation of v-ABL
protein tyrosine kinase. Cancer Res. 54:5131–5137. 1994.PubMed/NCBI
|
|
19
|
Niture SK and Jaiswal AK: Nrf2 protein
up-regulates antiapoptotic protein Bcl-2 and prevents cellular
apoptosis. J Biol Chem. 287:9873–9886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Q and Li W, Wan Y, Xia X, Wu Q, Chen
Y, Lai Z, Yu C and Li W: Amplified in breast cancer 1 enhances
human cholangiocarcinoma growth and chemoresistance by simultaneous
activation of Akt and Nrf2 pathways. Hepatology. 55:1820–1829.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yin XM, Oltvai ZN and Korsmeyer SJ: BH1
and BH2 domains of Bcl-2 are required for inhibition of apoptosis
and heterodimerization with Bax. Nature. 369:321–323. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niture SK and Jaiswal AK: Nrf2-induced
antiapoptotic Bcl-xL protein enhances cell survival and drug
resistance. Free Radic Biol Med. 57:119–131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang C, Wang HJ, Bao QC, Wang L, Guo TK,
Chen WL, Xu LL, Zhou HS, Bian JL, Yang YR, et al: NRF2 promotes
breast cancer cell proliferation and metastasis by increasing
RhoA/ROCK pathway signal transduction. Oncotarget. 7:73593–73606.
2016.PubMed/NCBI
|
|
24
|
Stein A, Atanackovic D and Bokemeyer C:
Current standards and new trends in the primary treatment of
colorectal cancer. Eur J Cancer. 47 Suppl 3:S312–S314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Robert J and Jarry C: Multidrug resistance
reversal agents. J Med Chem. 46:4805–4817. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Wang F, Li F, Zhang W, Shen Y,
Zhou D and Guo S: A multifunctional poly(curcumin) nanomedicine for
dual-modal targeted delivery, intracellular responsive release,
dual-drug treatment and imaging of multidrug resistant cancer
cells. J Mater Chem B Mater Biol Med. 4:2954–2962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baldwin PR, Reeves AZ, Powell KR, Napier
RJ, Swimm AI, Sun A, Giesler K, Bommarius B, Shinnick TM, Snyder
JP, et al: Monocarbonyl analogs of curcumin inhibit growth of
antibiotic sensitive and resistant strains of Mycobacterium
tuberculosis. Eur J Med Chem. 92:693–699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Negi N, Prakash P, Gupta ML and Mohapatra
TM: Possible Role of Curcumin as an Efflux Pump Inhibitor in Multi
Drug Resistant Clinical Isolates of Pseudomonas aeruginosa. J Clin
Diagn Res. 8:DC04–DC07. 2014.PubMed/NCBI
|
|
29
|
Fan YX, Abulimiti P, Zhang HL, Zhou YK and
Zhu L: Mechanism of reversal of multidrug resistance by curcumin in
human colorectal cancer cell line HCT-8/5-FU. Genet Mol Res.
16:162017. View Article : Google Scholar
|
|
30
|
Seo BR, Min KJ, Cho IJ, Kim SC and Kwon
TK: Curcumin significantly enhances dual PI3K/Akt and mTOR
inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma
Caki cells through down-regulation of p53-dependent Bcl-2
expression and inhibition of Mcl-1 protein stability. PLoS One.
9:e955882014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun Y, Zhang J, Zhou J, Huang Z, Hu H,
Qiao M, Zhao X and Chen D: Synergistic effect of cucurbitacin B in
combination with curcumin via enhancing apoptosis induction and
reversing multidrug resistance in human hepatoma cells. Eur J
Pharmacol. 768:28–40. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moghadamtousi SZ, Kadir HA, Hassandarvish
P, Tajik H, Abubakar S and Zandi K: A review on antibacterial,
antiviral, and antifungal activity of curcumin. Biomed Res Int.
2014:1868642014.PubMed/NCBI
|
|
33
|
Patel BB and Majumdar AP: Synergistic role
of curcumin with current therapeutics in colorectal cancer:
Minireview. Nutr Cancer. 61:842–846. 2009. View Article : Google Scholar : PubMed/NCBI
|
